Patents Assigned to The Board of Regents of the University of Texas System
  • Patent number: 11900383
    Abstract: Methods for generating fraud detection rules based on transaction data may include receiving historical transaction data, associating tags with each transaction, generating decision trees having root nodes and child nodes operably connected to the respective root nodes, determining at least one primary rule and at least one set of secondary rules associated with the at least one primary rule based on relationships between features of the transactions, assigning primary rules and sets of secondary rules to the at least one decision tree to populate the tree, extracting a plurality of rule sets including at least one primary rule and one or more secondary rules, determining an ordering of the plurality of rule sets; and determining a subset of rule sets from the ordered plurality of rule sets against which subsequently received transactions are compared against to determine if the subsequent transactions are fraudulent.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: February 13, 2024
    Assignees: Visa International Service Association, Board of Regents, The University of Texas System
    Inventors: Youxing Qu, Yiwei Cai, Dan Wang, Harishkumar Sundarji Majithiya, Roshni Ann Samuel, Susan Finnegan, Claudia Barcenas, Himanshu Chauhan
  • Patent number: 11896739
    Abstract: Biodegradable antimicrobial films are provided that are solid at room temperature and substantially liquefy in situ after implantation into a mammal, such as a human patient. Methods of using the films to cover a medical device, such as a breast implant, prior to insertion into a subject are also provided.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: February 13, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Rosenblatt, Issam Raad, Andrew P. Dennis
  • Patent number: 11896558
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: February 13, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • Publication number: 20240048411
    Abstract: A system for processing data, comprising a scoring system operating on a processor and configured to receive a channel sample and a noise sample and to generate a channel estimate and a sampling system operating on the processor and configured to receive a pilot channel sample and the channel estimate and to iteratively modify the channel estimate until a predetermined error rate is achieved.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 8, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Marius Arvinte, Jonathan I. Tamir
  • Publication number: 20240043483
    Abstract: The present disclosure provides biosensor cells and methods of use thereof. The disclosure provides, for example, methods of measuring a titer of or of detecting a seed tau protein in a sample, methods of detecting Alzheimer's disease (AD), or a neurodegenerative tauopathy disease or condition linked to tau protein aggregation, and methods for the identification of putative tau protein aggregation inhibitors or modulators.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 8, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Marc DIAMOND, Victor MANON, Jaime VAQUER-ALICEA, Brian HITT
  • Publication number: 20240043838
    Abstract: Compositions and methods for attenuating or preventing lymphoproliferation in a subject are provided. The subject may have, be suspected of having, or at risk of having a lymphoproliferative disease. The methods herein include administering to the subject a composition effective for decreasing WD repeat domain protein 37 (Wdr37) expression and/or activity.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 8, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Bruce Beutler, Evan D. Nair-Gill
  • Publication number: 20240047690
    Abstract: Lithiated metal organic frameworks, methods of manufacturing lithiated metal organic frameworks, for example, by binding a solvent molecule to the MOF structure to achieve a highly lithiated bound solvent metal organic framework having improved Li+-ion conductivity, and applications for use of the lithiated metal organic frameworks, for example, in various capacities in rechargeable lithium batteries.
    Type: Application
    Filed: February 10, 2022
    Publication date: February 8, 2024
    Applicants: ENERGY EXPLORATION TECHNOLOGIES, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Richelle LYNDON, Amit PATWARDHAN, Chris AFFOLTER, Karl P. LILLERUD, Teague EGAN, Nicholas Spencer GRUNDISH, Kevin Kruschka REIMUND, Benny Dean FREEMAN, John Bannister GOODENOUGH
  • Publication number: 20240043538
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Application
    Filed: November 17, 2022
    Publication date: February 8, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Carlo TONIATTI, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Bianka PRINZ, Nadthakarn BOLAND
  • Publication number: 20240043378
    Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
    Type: Application
    Filed: June 15, 2023
    Publication date: February 8, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Daniel J. SIEGWART, Kejin ZHOU
  • Patent number: 11891616
    Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to MeCP2 loss and/or misfunction, including RETT syndrome. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a MeCP2 polypeptide.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: February 6, 2024
    Assignee: Board of Regents of the University of Texas System
    Inventors: Steven J. Gray, Sarah Sinnett
  • Patent number: 11890344
    Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: February 6, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sarah Mayes, Christine Schmidt
  • Patent number: 11890320
    Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 6, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sean Morrison, Rui Yue
  • Patent number: 11892397
    Abstract: A pyrogenicity test method and assay of endotoxins allows for rapid and ultrahigh sensitivity testing of parenteral pharmaceuticals or medical devices that contact blood or cerebrospinal fluid by employing a Limulus Amoebocyte Lysate (LAL) assay monitored with a photonic-crystal biosensor. The photonic-crystal biosensor is capable of determining the presence of endotoxins in a test sample by detecting shifts in the resonant condition of an open microcavity affected by the changes in the refractive index of the analyte solutions used.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 6, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jing Yong Ye, Jonathan D. Scudder
  • Publication number: 20240035091
    Abstract: Provided herein is a 7-genes signature, an algorithm to evaluate a patient's risk score, and methods of use thereof. The methods provided herein include methods of use of a risk score to predict lung cancer patient survival and lung cancer patient likelihood to respond to adjuvant chemotherapy.
    Type: Application
    Filed: December 8, 2021
    Publication date: February 1, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yang XIE, Guanghua XIAO
  • Publication number: 20240034782
    Abstract: Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.
    Type: Application
    Filed: August 5, 2023
    Publication date: February 1, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Philipp E. Scherer, Shangang Zhao
  • Patent number: 11885861
    Abstract: 3D MRI images of the brain may be created and acquired. After administration of contrast, brain lesions and other abnormalities may be identified and isolated from the 3D MRI images, with each lesion serving as a region of interest (ROI). 3D region of contrast enhancement images may be created from segmented 3D MRI images and different regions of contrast enhancement of the brain lesion may be depicted. Saved regions of contrast enhancement may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D region of contrast enhancement images may be used to create 3D printed models of the isolated region of contrast enhancement. Analysis of the 3D brain region of contrast enhancement images and the 3D printed region of contrast enhancement models may enable a more efficient and accurate way of determining brain lesion risk factors and effective treatment regimens.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 30, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Darin Okuda
  • Patent number: 11883236
    Abstract: A diagnostic imaging device includes a probe that uses both an ultrasound transducer and frequency-domain diffuse optical imaging (FD-DOI) to assist with locating and diagnosing sub-tissue anomalies. According to one aspect, the diagnostic imaging device relates to a clip-on cap that can be utilized with existing ultrasound transducers. The diagnostic imaging device described herein can be utilized for image-guided needle biopsy to regions where prostate tissues are highly suspicious for high-grade cancer, as well as for image guided interventions, such as cryotherapy, photodynamic therapy, and brachytherapy for early-stage or localized prostate cancer.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 30, 2024
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Hanli Liu, Venkaiah C. Kavuri
  • Patent number: 11884765
    Abstract: Disclosed herein are hydrogel compositions comprising a triblock copolymer having a formula A-B-A, wherein A is a polycaprolactone (PCL) block or a polyvalerolactone (PVL) block and B is a polyethylene glycol (PEG) block. Also disclosed are methods of making a hydrogel comprising providing a photoinitiator and a triblock copolymer having a formula A-B-A, wherein the triblock copolymer comprises one or more ethylenically unsaturated moieties; and photocrosslinking the triblock copolymer, thereby forming a hydrogel.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: January 30, 2024
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, NORTHEASTERN UNIVERSITY
    Inventors: Yi Hong, Guohao Dai, Cancan Xu, Wen-han Lee
  • Patent number: 11883423
    Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: January 30, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhengrong Cui, Dharmika Lansakara-P.
  • Patent number: 11884872
    Abstract: Described herein are methods of cementing at least a portion of a well comprising feeding a magnetorheological cementitious slurry to a well and applying a magnetic field to the magnetorheological cementitious slurry concurrent with at least a portion of said feeding step to cause a mechanical response in said magnetorheological cementitious slurry in the well. Also disclosed herein are methods of temporarily blocking at least a portion of a well comprising providing a magnetorheological fluid in a well, applying a magnetic field to cause a mechanical response in said magnetorheological fluid thereby blocking at least a portion of the well, and removing the magnetic field to unblock the portion of the well. Also disclosed herein is a magnetorheological cement.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: January 30, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric Van Oort, Kenneth M. Cowan, Sriramya Duddukuri Nair, Raissa Ferron